Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design

John Mascarenhas, Claire N. Harrison, Jean Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro M. Vannucchi, Tymara Berry, Denise Redding, Laurie Sherman, Souria Dougherty, Lixian Peng, Libo Sun, Fei Huang, Ying Wan, Faye M. Feller, Aleksandra Rizo, Srdan Verstovsek

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Imetelstat, a first-in-class telomerase inhibitor, demonstrated meaningful clinical benefit including a robust symptom response rate and potential overall survival benefit in IMbark, a phase II study in intermediate-2 or high-risk myelofibrosis (MF) patients who have relapsed after or are refractory to JAK inhibitors. We describe the rationale and design for the phase III trial, IMpactMF (NCT04576156), an open-label evaluation of imetelstat versus best available therapy, excluding JAK inhibitors, in MF patients refractory to JAK inhibitor. Imetelstat 9.4 mg/kg is administered as an intravenous infusion every 21 days. Primary objective is to assess overall survival. Secondary objectives include symptom and spleen responses, progression-free survival, clinical response assessment, bone marrow fibrosis reduction, safety and pharmacokinetics. Biomarker, cytogenetics and mutation analyses will be performed.

Original languageEnglish
Pages (from-to)2393-2402
Number of pages10
JournalFuture Oncology
Volume18
Issue number22
DOIs
StatePublished - Jul 2022

Keywords

  • JAK inhibitor
  • biomarkers
  • fedratinib
  • imetelstat
  • myelofibrosis
  • pacritinib
  • ruxolitinib
  • safety
  • survival
  • telomerase

Fingerprint

Dive into the research topics of 'Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design'. Together they form a unique fingerprint.

Cite this